Nanjing Vishee Medical Technology Co., Ltd
SSE:688580.SS
47.96 (CNY) • At close June 9, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 400.059 | 462.223 | 321.621 | 430.044 | 378.367 | 318.873 | 207.781 | 144.495 | 95.904 | 80.504 | 58.161 | 48.853 |
| Cost of Revenue
| 138.226 | 130.514 | 88.517 | 108.454 | 99.762 | 83.819 | 53.679 | 37.88 | 25.551 | 21.886 | 17.345 | 15.316 |
| Gross Profit
| 261.832 | 331.709 | 233.104 | 321.591 | 278.606 | 235.055 | 154.102 | 106.615 | 70.353 | 58.619 | 40.816 | 33.537 |
| Gross Profit Ratio
| 0.654 | 0.718 | 0.725 | 0.748 | 0.736 | 0.737 | 0.742 | 0.738 | 0.734 | 0.728 | 0.702 | 0.686 |
| Reseach & Development Expenses
| 50.613 | 57.654 | 43.733 | 63.52 | 34.287 | 27.383 | 18.543 | 13.041 | 8.987 | 0 | 0 | 1.819 |
| General & Administrative Expenses
| 11.133 | 17.391 | 9.614 | 14.127 | 13.015 | 9.487 | 9.499 | 6.723 | 9.693 | 17.291 | 12.536 | 12.059 |
| Selling & Marketing Expenses
| 36.442 | 123.635 | 91.537 | 78.099 | 72.054 | 75.131 | 53.17 | 41.93 | 32.065 | 16.242 | 14.301 | 14.015 |
| SG&A
| 47.575 | 141.026 | 101.151 | 92.226 | 85.07 | 84.617 | 62.668 | 48.653 | 41.758 | 33.532 | 26.837 | 26.075 |
| Other Expenses
| 52.141 | -15.414 | 17.998 | 7.404 | 13.048 | 11.854 | 3.719 | -0.505 | 6.589 | 0 | 5.399 | 7.176 |
| Operating Expenses
| 150.329 | 183.266 | 162.883 | 163.15 | 132.405 | 123.855 | 84.931 | 61.19 | 52.081 | 30.57 | 27.805 | 26.719 |
| Operating Income
| 111.503 | 148.442 | 104.456 | 194.679 | 164.86 | 114.675 | 72.016 | 46.849 | 20.341 | 23.842 | 17.146 | 7.717 |
| Operating Income Ratio
| 0.279 | 0.321 | 0.325 | 0.453 | 0.436 | 0.36 | 0.347 | 0.324 | 0.212 | 0.296 | 0.295 | 0.158 |
| Total Other Income Expenses Net
| 1.776 | 1.569 | 1.384 | 2.701 | 1.219 | 0.124 | 1.344 | -0.111 | 6.589 | 3.615 | 5.399 | 7.176 |
| Income Before Tax
| 113.279 | 150.012 | 105.84 | 197.381 | 166.079 | 114.799 | 73.36 | 46.738 | 26.931 | 30.313 | 22.546 | 14.892 |
| Income Before Tax Ratio
| 0.283 | 0.325 | 0.329 | 0.459 | 0.439 | 0.36 | 0.353 | 0.323 | 0.281 | 0.377 | 0.388 | 0.305 |
| Income Tax Expense
| 11.31 | 13.753 | 12.014 | 19.844 | 22.945 | 15.908 | 10.635 | 6.548 | 3.783 | 2.226 | 0.767 | 0.638 |
| Net Income
| 101.969 | 136.259 | 93.826 | 177.812 | 143.659 | 99.718 | 63.364 | 40.338 | 23.148 | 28.127 | 21.749 | 13.993 |
| Net Income Ratio
| 0.255 | 0.295 | 0.292 | 0.413 | 0.38 | 0.313 | 0.305 | 0.279 | 0.241 | 0.349 | 0.374 | 0.286 |
| EPS
| 1.07 | 1.43 | 0.98 | 1.86 | 1.76 | 1.39 | 0.88 | 0.57 | 0.46 | 0.56 | 0.44 | 0.28 |
| EPS Diluted
| 1.07 | 1.42 | 0.98 | 1.85 | 1.76 | 1.39 | 0.88 | 0.57 | 0.46 | 0.56 | 0.44 | 0.28 |
| EBITDA
| 136.563 | 173.323 | 125.002 | 209.07 | 175.54 | 123.801 | 78.04 | 47.81 | 18.962 | 24.686 | 13.684 | 7.4 |
| EBITDA Ratio
| 0.341 | 0.375 | 0.389 | 0.486 | 0.464 | 0.388 | 0.376 | 0.331 | 0.198 | 0.307 | 0.235 | 0.151 |